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Mutations in DNA methyltransferase 3A (DNMT3A) gene were recently demonstrated in acute myeloid
leukemia(AML). Approximately 20% patients with AML carry DNMT3A gene mutations and was associated with
a poor clinical outcome. but its clinical implications in Chinese AML patients are largely unknown. We
analyzed 101 adult AML patients in china and found 14 patients (13.9%) harboring this mutation. 9 patient
with M5, 2 patients with M1, 2patient with M2 and 1 patient with M3. We identified 11 missense mutation,2
nonsense and 30 bp deletion encompassing DNMT3A. The most common of them was predicted to affect
882Arg(in 4 patients). Double mutations were detected in two cases.10 of 33(43.5%). DNMT3A mutations
occurred more frequently in older (age > 50y,p < 0.05) and the outcome is too badly for these patients. We
concluded that DNMT3A mutations are highly recurrent in AML and is associated with distinct clinical and
biologic characteristics and seems to be a useful as a prognostic marker.
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Acute Myeloid Leukemia (AML) is a heterogeneous malig-
nancy that can be classified by morphological, cytogenetic
and molecular genetic criteria, Currently, cytogenetic ana-
lysis at diagnosis allows for risk-stratification of AML into
a useful prognostic marker and intermediate risk [1], To
some extent, Treatment protocols are adapted in an at-
tempt to improve survival and decrease treatment-related
toxicity. Unfortunately, prognostic implications have not
been reliably established for AML in the intermediate
risk category. In recent years, molecular analysis has
identified novel markers with prognostic relevance in
this diverse group. For example, AML with internal tan-
dem duplication (ITD) in the fms-like tyrosine- kinase-3
gene (FLT3) carries a poor prognosis [2,3]. Molecular stud-
ies have pinpointed recurrent somatic mutations in NPM1,
CEBPα, TET2,MLL-PTD and fusion proteins such as
PML-RARα and CBFB-MYH11, which characterize spe-
cific types of AML [4].
The human DNA methyltransferase gene (DNMT1,
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reproduction in any medium, provided the orthe addition of a methyl group to the fifth position of cyto-
sine,generating 5 methylcytosine, by this mechanism, the
DNA methyltransferase mediate the downregulation of
target gene via the methylation of upstream CPG islands.
Gene mutation in DNA methyltransferase which alter en-
zyme function have now been described in acute leukemia,
Yamashita et al. reported [5] 4.1% somatic mutation of
DNA methyltransferase (DNMT3A) at amino-acid Arg882
in leukemia, Later Ley [6] et al. found 22.1% DNMT3A
mutations in adult normal karyotype AML genome and
Chen SJ also discovered gene mutations in DNMT3A
in patients with M5 (20.5%) and with 13.6% of M4 sub-
type [7]. those results above indicated that DNMT3A
mutations were independently and significantly associated
with decreased survival in adult AML. in order to analyze
the influence of DNMT3A mutation on the prognosis and
survival of AML. In this study, RNA from bone marrow
cells of untreated AML patients from the Chinese patients
were examined by using PCR and sequence analysis, sim-
ultaneously chromosome examination and immunophe-
notype were also performed.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients and samples
There were 101 patients aged 16–76 years with AML in
this study, those were newly diagnosed AML which were
classified according to French-American-British(FAB)
classification system, including M0(n = 2),M1(n = 4),
M2(n = 41), M3(n = 25), M4(n = 6),M5(n = 21), M6(n = 2).
All of them were diagnosed and treated in the Zhongshan
Hospital of Xiamen University from July 2008 to Dec
2010. Bone marrow(BM) aspirates or peripheral blood
(PB WBC > 50 × 109) sample were collected at the first
visit and in accordance with guidelines from the eth-
ics committee of the hospital.
Cytogenetic analysis
Bone marrow cells were harvested directly before chemo-
therapy according to the study [8] , the metaphase chro-
mosomes were banded by the G-banding techniques and
karyotyped according to the International System for
Human Cytogenetic Nomenclature.
Immunophenotyping
A panel of monoclonal antibodies to myeloid-associated
antigens including CD13, CD14, CD33, as well as lymphoid-
associated antigens including CD2, CD5, CD7, CD19,
CD20, and lineage nonspecific antigens HLA-DR, CD34
were used to characterize the phenotypes of the leukemia
cell with Epics XL4 flow cytometer (Beckman Coulter,
America).
RNA preparation
Total RNA was isolated using RNAprep pure Blood Kit
(Tiangen Biotech, China), according to the manufacturer’s
instructions,followed by treatment with RNase-free DNaseI
to remove contaminating genomic DNA. The RNA was
dissolved in RNase-free H2O, checked for purify and con-
centration with ND-1000 UV–vis Spectrophotometer
(Nanodrop Technologies, USA) and stored at −80°C until
to be used.
Reverse transcription PCR(RT-PCR)
Reverse transcription was performed with T3 Thermo-
cycle (Biometra, Germany), total RNA (2 μg) was mixed
with 10 mmol dNTPs and 25 pmol random primers
(TOYOBO, Japan), incubated at 65°C for 5 minutes,
chilled immediately on ice, followed by addition of 20 U
RNase inhibitor, 1 RT buffer, 100 U MMLV reverse
transcriptase (Sangon, China) and RNase-free water to
make up a volume of 20 μl. RT reaction was incubated
at: 37°C 10 minutes; 42°C 60 minutes; 70°C 10 min. Re-
sultant complementary DNA (cDNA) was diluted with
180 μl ddH2O (10 ng/ μl RNA equivalent) and was
stored at −20°C.Mutation analysis
The DNMT3A was amplified by 2 pairs of primers and
sequenced by the same ones. The sequences of these PCR




The reference sequence was NM_022552.3 for mRNA.
In every 25 μL of PCR reaction, there were 1 SSP buffer
(67 mM Tris–HCl, 16 mM (NH4)2SO4, 0.01% Tween
20, pH 8.8), 0.2 mM dNTPs, 2.5 mM MgCl2, 0.4 uM
each tagged primer, 0.5 U TaqHS DNA polymerase
(Takara, Japan), and 5 μl of cDNA. The amplification
was performed in a Thermal Cycler PCR instrument
(Bioer, China) under the following conditions: 95°C
3 minutes; 10 cycles of touchdown PCR, 95°C 20 seconds,
65°C −60°C (decreased by 0.5°C per cycle) 20 seconds,
72°C 90 seconds;30 cycles of 95°C 20 seconds, 60°C
20 seconds, 72°C 90 seconds and finally,72°C 7 min.The
PCR products were verified by electrophoresis and
sequencing. Clone the DNA fragments with overlap
peak into pMD18-T vector (Takara, Japan) and sequen-
cing.When the mutations were not obvious because of
location near the primers,sequencing from the other
direction was done to solve this issue.
Statistical analysis
The discrete variables of patients with and without gene
mutation were compared using the χ2 tests, but if the
theoretical frequency was smaller than 5,correction for
continuity was used All statistical analyses were per-
formed with SPSS 16.0 software(SPSS Inc).
Results
DNMT3A mutations
In my study, 101 samples from new diagnostic AML
were detected by PCR amplification of entire coding
region of DNMT3A, the detection rate of DNMT3A
mutations in AML patients was 13.9%(14/101), in-
cluding 2 patients of M1, 2 patients of M2,1 patient
of M3 and 9 patients of M5(42.9%). (Table1) .the type
of mutations was 11 missense, 2 nonsense and 1 dele-
tion mutations.respectively. single nucleotide varia-
tions included 2645 G > A(Arg882His), 914 G > A
(nonsense), 2096 G >A(Gly699Asp), 2501C >T(Thr834IIe),
55C >T(Arg19Trp), 2202C >A(Phe734Leu) and 2644 C >
T(Arg882Cys).(,Fig-1) The most common mutations are
predicted to affect amino- acid Arg882 (in 6 patients) and
Thr834(in 2 patients).We also detected a 30 bp deletion
according to sequencing (Figure 1, patient 40). Double
point mutation was also detected in 2 patient (Figure 2).
DNMT3A mutation (2645 G >A) was found in BM sample
of the old patient with M5, this is the same with that of
Ewalt reported (Figure 1 patient 77) [9].
Table 1 Clinical features of the Patients with DMNT3A mutations
No Age sex FAB Cytogenetics WBC X10^9/L CD33+/CD34+ DNMT3A Chemo-response result
7 65 F M1 normal 36.6 6%/92% 2645 G > A CR Dead(12 M)
19 72 M M2 normal 57.2 99%/32% 914 G > A No Dead(6 M)
22 55 M M5 normal 112.9 99%/16% 2645 G > A CR Alive(SCT)
38 58 F M5 t(6;9) 12.1 56%/55% 2096 G > A CR Dead(10 M)
40 56 F M2 inv(9) 15 20%/82% 30 bp del 2502-2531 CR Dead(SCT)
47 31 F M5 del(13) 1.5 95%/27% 2501 C > T N0 Dead(3 M)
48 20 F M5 normal 30.4 4.5%/71% 2501 C > T N0 Dead(3 M)
53 53 F M3 t(4;17) 7.9 82%/1.6% 55 C > T CR Alive
56 54 F M5 normal 2.19 95%/28% 2202 C > A CR Relapse(6 M)
68 52 M M5 normal 28.8 97%/42% 2644 C > T No Dead(6 M)
77 76 M M5 normal 67 No 2645 G > A Arg882His CR Dead(13 M)
89 76 M M1 normal 17.3 CD13 CD34 1906 G > A 2191 T > C NR Dead(3 M)
94 61 F M5 normal 132 CD7CD13CD33 2141C > G NO Dead(1 M)
100 46 M M5 normal 4.5 CD13CD34 1792C > T 2375 G > A NR Dead(1 M)
CR Complete remission, No no chemotherapy, NR not remission, M month.
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Of the mutated patients, AML-M5 subtype had higher
DNMT3A mutation rate than those with other subtype.
Cytogenetic data showed that 10 cases with DNMT3A
mutation was normal karyotypes AML patients (71.45%,
p > 0.05). No DNMT3A mutations were found in AML
samples with cytogenetic findings associated with a favor-
able (except 1 patient with M3). In all of positive patients,Figure 1 Sequencing results for patient 7(2645 G > A), patient 19(914
(30 bp del 2502-2531 bp) and patient 47(2501 C > T), Patient 40 harb8 patients were female (57.1%, p > 0.05), 11 patients were
older than 50 years (78.6%, p < 0.05). we also discovered
that DNMT3A mutations were associated with high ex-
pression of CD33 or CD34, After having been treated by
induction chemotherapy, all patients achieved complete
hematological remission(76.5%), but 4 patients refused to
receive chemotherapy, after 12 monthes follow up, only 2
patients were alive including 1 M3 patient.G > A), patient 22 (2645 G > A), patient 38(2906 G > A), patient40
ors a 30 bp deletion and shows a overlap peak.
Figure 2 Sequencing results for patient 89, the double point DNMT3A mutation was K: 1906 G > A,L:2191 T > C.
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Epigenetic mechanisms play a crucial role in regulation
of gene expression and DNA methylation catalyzed by
specific DNA methyltransferase and DNMTs is an im-
portant epigenetic control of gene expression and the
maintenance of genome integrity. Many DNMTs appear
to be present in human and have a different role in
establishing and maintaining the DNA methylation pat-
tern including DNMT1, DNMT2, DNMT3A, DNMT3B
and DNMT3L [10,11]. DNMT1 is the primary enzyme
responsible for copping methylation patterns after
DNA replication while DNMT2 does not methylate
DNA but instead methylates small RNA,. DNMT3A
and DNMT3B are paralogous enzymes responsible for
de novo DNA cytosine methylation. DNMT3L plays a
key role in allowing DNA methylation during the mat-
uration of germ [12]. Mouse studies showed that
DNMT is required for hematopoietic stem cell self re-
newal, regulation of proliferation and normal myeloid
and lymphoid differentiation. By contrast, deletion of
DNMT3A and DNMT3B in mouse hematopoietic stem
cells impaired stem cell self renewal, the frequent
DNMT3A mutations may be an parts of pathogenesis
in acute myeloid leukemia [13].
In this study, we report the frequency of DNMT3A
mutations in patients with de novo AML and their
Clinical features compared to the patients without
DMNT3A mutations. We sequenced all coding exon
of DNMT3A using DNA from leukemia cells and
identified 14 heterozygous mutations (13.9%). Amino
acid R882, located in the methyltransferase domain
of DNMT3A, was the most common mutation site.
Our results showed that the rate of DNMT3A gene
mutations in Chinese AML patient is more common
and AML-M5 was more higher than other type(9/21)
the alterations of Arg882 are also the most frequent
mutation in Chinese AML patients. We also found one
AML-M3 patient who carried t(4; 17) chromosomalabnormality carry DNMT3A gene mutation and this is
not reported by other papers [6,7].
Our results indicated that most of patients(11/14)
with DNMT3A mutation died of leukemia after 6 months
treatment, two patient were alive due to allogeneic stem
cell transplant and AML-M3 type. The last one was one
relapse. Although it is unclear if DNMT3A mutation can
affect survival of AML patient, this fact was accord with
concept that DNMT3A mutation could be a dependent
factor on AML patients. In concurrence with other
reporters, there was no significant association between
DNMT3A mutations and sex, high WBC or increased
blast percentage in the bone marrow at diagnosis. But
the high expression of CD33 or CD34 on AML cells
was very common., DNMT3A mutation were found in
patients above 50 years of age, this is agreement with
previous studies. Although DNMT3A gene mutation
was almost never found in AML-M3 subtype, this pa-
tient carried t(4; 17) chromosomal abnormality and
PML-RARα fusion gene, it may be associated with a
poor prognosis for no-classical acute promyelocytic
leukemia.
To conclude, it seems that DNMT3A mutations are
consistently present in approximately 10% of AML cases,
the role of DNMT3A mutations on leukemogenesis was
still unclear. Future studies will help to illuminate the
pathogenesis of AML, we need to develop a method of
quick determination of the whole gene mutations and
evaluate the influence of DNMT3A mutation on treat-
ment response and survival in a larger sample.
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